智翔金泰：自主研发赛立奇单抗注射液纳入2025年国家医保目录

Core Viewpoint - The company announced that its self-developed monoclonal antibody injection, Sairiqi (Jinlixi), has been successfully included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, effective from January 1, 2026, with an agreement valid until December 31, 2027 [1] Group 1 - The drug is classified as a Class I biological product and a Class B prescription drug, intended for the treatment of moderate to severe plaque psoriasis and ankylosing spondylitis [1] - The corresponding indications for the drug are expected to receive market approval in August 2024 and January 2025, respectively [1] - Inclusion in the medical insurance list may facilitate the market promotion and sales of the product, although sales are subject to various influencing factors, leading to uncertainty [1]